#United States #Los Angeles #Prostate Cancer #Actinium Pharmaceuticals #ATNM-400

Actinium Pharmaceuticals Shines at SNMMI 2026

Actinium Pharmaceuticals, Inc. made a significant impact at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, held in Los Angeles, where they presented groundbreaking findings on their novel prostate cancer treatment, ATNM-400. This latest research showcases
how ATNM-400 overcomes resistance to currently approved androgen receptor pathway inhibitors (ARPIs) and offers adaptable dosing options for patients.

Key Highlights

New evidence revealed that ATNM-400 remains highly effective in prostate cancer cells and tumors resistant to all three FDA-approved ARPIs: enzalutamide, apalutamide, and darolutamide. In a robust comparison, ATNM-400 not only showed a dominant performance against apalutamide and darolutamide in ARPI-resistant tumor models, but it also displayed promising results when combined with these drugs, leading to sustained complete responses in many cases.

Moreover, ATNM-400 proved advantageous in terms of safety and dosing flexibility. As indicated in the presentation, it can be administered either as a single bolus or in multiple doses, with minimal off-target toxicity, reinforcing its potential for non-disruptive integration into existing treatment regimens.

Overcoming Existing Limitations

High-performance outcomes are crucial, especially given that around 50,000 patients each year exhaust the currently available ARPI therapies. With its unique mechanism of action, ATNM-400 targets a non-PSMA antigen relevant to aggressive prostate cancer biology, allowing for effective tumor cell destruction irrespective of PSMA expression or androgen receptor activity. This strategic advantage sets it apart from existing PSMA-directed therapies like 177Lu-PSMA-617 and 225Ac-PSMA-617.

In preclinical studies, ATNM-400 showed superior tumor inhibition rates, achieving 94% tumor growth reduction as a standalone treatment compared to just 32% and 5% for apalutamide and darolutamide, respectively. When used in combination with these ARPIs, ATNM-400 yielded a remarkable tumor growth inhibition of 107%, with complete responses in over half of the tested subjects. This evidence presents ATNM-400 not merely as an adjunct therapy but as a promising standalone option for advanced patients facing limited choices due to ARPI resistance.

Market and Patient Opportunity

The implications of these findings are vast, given the growing market for prostate cancer treatments, projected to exceed $12 billion annually. Actinium anticipates a substantial patient demographic of over 100,000 individuals annually may benefit from ATNM-400, especially those who are either resistant to current ARPIs or fall into the PSMA-low or PSMA-negative categories where there are currently no approved targeted options.

Actinium's Chairman and CEO, Sandesh Seth, emphasized the pressing need for effective treatments in this area, acknowledging that ARPI resistance represents a significant hurdle for many patients. The data presented at SNMMI 2026 opens up hope for those impacted by this treatment landscape, as ATNM-400 demonstrates not only potent efficacy but also a clean safety profile across diverse administration regimens.

Looking Ahead

The promising results from the studies presented at SNMMI 2026 position ATNM-400 as a potentially transformative therapy for advanced prostate cancer. Actinium is committed to advancing the clinical development of this innovative treatment and plans to share further insights and updates in upcoming months. As they move forward, they remain focused on addressing one of oncology's major challenges: the treatment of patients with resistant prostate cancer and ultimately enhancing patient outcomes.

In summary, Actinium Pharmaceuticals has set the stage for potential breakthroughs in prostate cancer therapy with ATNM-400, offering patients and clinicians a renewed sense of hope in what has been a challenging treatment environment. Through innovative approaches to radiotherapy, Actinium aims to redefine cancer treatment and improve the lives of countless patients worldwide.